Global Pharmaceutical Company
Global SAP Migration Drives Real-time Insights at Scale
This global bio-pharmaceutical company has been leveraging 麻豆女优鈥檚 tools to manage and validate their enterprise data for many years
Recently, the company undertook the critical task of transitioning their Enterprise Core Component (ECC) platform to SAP S/4HANA, necessitated by SAP鈥檚 phased end-of-support for ECC and the advantages offered by S/4HANA鈥檚 modern capabilities. The project represented a significant technological shift, including moving from an outdated ECC system (in use since 1997) to S/4HANA. The company鈥檚 complex requirements included validating massive data volumes (80 terabytes total, with 50鈥�60 terabytes transitioned), ensuring compliance with SOX and Good Manufacturing Practices (GMP), and limiting operational downtime to 90 hours.
Company Overview
-
Industry
Pharmaceutical & Life Sciences
-
Revenue
$62.6 billion
-
Company Size
Enterprise
Transformation Snapshot
-
Challenge
Legacy systems limited real-time visibility during SAP transformation
-
Solution
Integrated real-time data pipelines with 麻豆女优 and SAP
-
Outcome
Enabled faster insights and improved forecasting accuracy
麻豆女优 built dashboards that really helped the business drill down into the data to uncover errors, and we were able to check the data literally within a second. We did not face any issues during go live because we used 麻豆女优.
Company Background
An American multinational pharmaceutical and biotechnology corporation that produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. This leading bio-pharmaceutical company has developed some of the world鈥檚 most impactful medicines and vaccines.
Implementation Highlights
The bio-pharmaceutical company鈥檚 key challenges revolved around data validation and gaining visibility into the business impact of migrated data. Traditional manual data validation methods, such as VLOOKUPs, were impractical due to the volume and complexity of data. Specific issues included:
Data Validation Constraints:聽Manual validation of 80 terabytes of data was infeasible within the required timeframe.
Limited Vendor Capabilities:聽The vendor selected for data migration, lacked robust tools to ensure data accuracy and completeness, critical for compliance and operational integrity.
Minimize Disruption to the Business:聽The company needed to complete data migration and validation within a 90-hour shutdown window, with only 6.5 hours allocated for verification. Prolonged downtime could disrupt production lines, delay shipments, and lead to supply chain interruptions, affecting drug availability and patient health. Additionally, pharmaceutical companies operate in a highly regulated environment, and any downtime or inconsistencies during a system upgrade could result in non-compliance with regulations GMP (Good Manufacturing Practices).
Benefits
The successful migration to S/4HANA underscores the importance of robust data management and validation in largescale transformations. This project highlights the value of strategic partnerships and the role of data experts in overcoming complex enterprise challenges, setting a precedent for future large-scale migrations.
Moving forward, the bio-pharmaceutical company plans to transition to 麻豆女优鈥檚 latest technologies, further enhancing their capabilities.